A phase II study of triazinate (NSC 139105) in advanced colorectal carcinoma
A phase II study of triazinate (NSC 139105) in advanced colorectal carcinoma
复制标题
三嗪酸盐 (NSC 139105) 治疗晚期结直肠癌的 II 期研究
作者：
Robert H. McCreary;C. Moertel;A. Schutt;M. O’connell;R. Hahn;R. J. Reitemeier;J. Rubin;S. Frytak
本文报告28例晚期结直肠癌患者用三嗪酯（贝克氏抗肿瘤药，NSC 139105）单药化疗。使用的剂量为250 mg/m2静脉内，每天给药，连续三天。患者在第三周、第六周进行评估，然后每月进行一次评估，直到进展明显。各种免疫决定因素（即，在给药前和每次重新评价时获得DNCB致敏、免疫球蛋白、回忆皮肤试验、淋巴细胞胚细胞生成和循环淋巴细胞、T细胞和B细胞）。主要不良反应为皮炎、口腔炎、腹泻、恶心、嗜睡和白细胞减少。三嗪酯对检测的免疫决定因素无明显影响。有1例完全缓解，4例部分缓解，客观消退率为18%。本研究提示，三嗪酯对晚期大肠癌有一定的疗效，但疗效有限。癌症40：9 - 13，1977年。
Triazinate (Baker's Antifol, NSC 139105) was given to 28 patients as a single agent in the chemotherapy of advanced colerectal carcinoma. The dosage utilized was 250 mg/m2 intravenously, administered daily in three consecutive days. Patients were evaluated at three weeks, six weeks, and then monthly until progression was evident. Various immunologic determinants (i.e., DNCB sensitization, immunoglobulins, recall skin tests, lymphocyte blastogenesis, and circulating lymphocytes, T‐cells and B‐cells) were obtained prior to treatment and at each re‐evaluation. The principal side effects were dermatitis, stomatitis, diarrhea, nausea, somnolence, and leukopenia. There was no discernable effect of Triazinate on the immunologic determinants tested. There was one complete response, and four partial responses, for an objective regression rate of 18%. This study suggests that Triazinate has a definite, though limited, effect on advanced colorectal carcinoma. Cancer 40:9–13, 1977.